| 2026-08-06 | Press release | Press Release |
| 2026-07-01 | Presentation | Download PDF (opens in new window) |
| 2026-06-29 | Presentation | Lumvoa™ (veligrotug-vvze) FDA Approval |
| 2026-06-29 | Press release | Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid E |
| 2026-06-26 | Press release | Download , Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment o |
| 2026-06-03 | Press release | Viridian Therapeutics to Participate in Upcoming June Investor Conferences |
| 2026-05-27 | Press release | Download , Viridian Therapeutics to Participate in Upcoming June Investor Conferences, May 27, 2026, (opens in new windo |
| Press release | Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress |
| 2026-05-06 | Press release | Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 203 |
| 2026-05-05 | Presentation | REVEAL-2 Phase 3 Topline Results |
| 2026-05-05 | Press release | Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress |
| 2026-05-05 | Press release | Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock |
| 2026-05-05 | Press release | Download , Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in C |
| 2026-05-05 | Press release | Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyr |
| 2026-03-30 | Presentation | REVEAL-1 Phase 3 Topline Results |
| 2026-03-30 | Press release | Download , Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in A |
| 2026-03-30 | Press release | Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyro |
| 2026-02-26 | Press release | Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-01-08 | Press release | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-01-06 | Press release | Download , Viridian Therapeutics Prepares for Transformational 2026, January 6, 2026, (opens in new window) |
| 2025-02-27 | Press release | Press Release(opens in new window) |
| 2024-11-12 | Press release | Press Release(opens in new window) |
| 2024-08-08 | Press release | Press Release(opens in new window) |
| 2024-05-08 | Press release | Press Release(opens in new window) |
| 2024-02-27 | Press release | Press Release(opens in new window) |
| 2023-11-13 | Press release | Press Release(opens in new window) |
| 2022-11-14 | Press release | Press Release(opens in new window) |
| 2022-08-15 | Press release | Press Release(opens in new window) |
| 2022-05-12 | Press release | Press Release(opens in new window) |
| 2022-03-10 | Press release | Press Release(opens in new window) |
| 2021-11-04 | Press release | Press Release(opens in new window) |
| 2021-08-11 | Press release | Press Release(opens in new window) |
| 2021-05-06 | Press release | Press Release(opens in new window) |
| 2021-03-25 | Press release | Press Release(opens in new window) |
| 2020-08-05 | Press release | Press Release(opens in new window) |
| 2020-03-11 | Press release | Press Release(opens in new window) |
| Press release | Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results |
| Press release | Press Release |
| Press release | View full release |
| Press release | View full release |